Literature DB >> 6118939

A stable, reproducible radioreceptorassay for thyrotropin binding inhibiting immunoglobulins (TBII).

H Bliddal.   

Abstract

A radioreceptorassay for thyrotropin binding inhibiting immunoglobulins (TBII) is presented. A stable reproducible method was established based on the use of thyroid glands obtained by autopsy for the preparation of a highly purified plasma membrane from human thyroid homogenate. Lower detection limit for TSH was below 5 miu/l. The TBII activity was measured in a crude IgG precipitate from serum and the results were calculated as an index value compared to normal controls, the mean of which was defined as 1.00. The binding of [125I] TSH to this membrane preparation was stable for more than 6 months. Interassay variations of the TBII index in three ranges were 1.30 +/- 0.19, 0.37 +/- 0.08 and 0.04 +/- 0.07 (mean +/- SD) over a period of 6 months. The intra-assay variations of the TBII index in three ranges were 1.30 +/- 0.08, 0.46 +/- 0.03 and 0.09 +/- 0.03 (mean +/- SD). Seventy-six of 116 patients with untreated Graves' disease had index values below the reference interval and TBII was also detected in 4 of 14 patients with multinodular goitre. The value of the TBII index in patients with untreated Graves' disease was significantly correlated to S-T3, the 4 h [131I] uptake and the 20 min [99mTc] uptake. No significant correlation between the TBII index and long-acting thyroid stimulator (LATS) measured in a bioassay was found. However, the LATS-positive patients also had positive TBII index.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6118939     DOI: 10.3109/00365518109090481

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  4 in total

1.  Thyroid function in patients with Pendred's syndrome.

Authors:  J Friis; T Johnsen; U Feldt-Rasmussen; K Bech; T Friis
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

2.  10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb).

Authors:  J Hensen; P Kotulla; R Finke; K Badenhoop; K Koppenhagen; H Meinhold; H Schleusener
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

3.  The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.

Authors:  H Bliddal; K Bech; K Siersbaek-Nielsen; T Friis
Journal:  J Endocrinol Invest       Date:  1983-08       Impact factor: 4.256

4.  Thyroid stimulating antibodies in rheumatoid arthritis: an in vitro phenomenon.

Authors:  C Kirkegaard; K Bech; H Bliddal; B Danneskiold-Samsoe; U Feldt-Rasmussen
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.